BMS' Opdivo denied first-line melanoma indication; Biogen's long-acting hemophilia med nabs EU approval;

> Fresh off an FDA victory just days ago, Bristol-Myers Squibb's ($BMY) Opdivo hit an obstacle in melanoma; the agency denied a first-line use in that disease, saying it needs more data in patients with BRAF mutations. Report

> Biogen ($BIIB) and Sobi's new hemophilia A med Elocta won approval in Europe, the first longer-acting treatment in that disease type for the region. Release

> China is zeroing in on drugs made by domestic pharma companies, threatening growth among multinationals that have benefited not only from newer products but from their own "branded generics." Report

> Spain's Almirall agreed to buy dermatology specialist Poli Group, part of its bid to move into specialty meds after selling off its respiratory drugs to AstraZeneca ($AZN) last year. Release

> Sanofi Pasteur says the first doses of its new injectable polio vaccine, ShanIPV, will soon be rolling out in India, a market where oral polio vaccines are customary. Release

And Finally... Blue Latitude Health picked up a PMEA award for its work on Eli Lilly's ($LLY) Medical Information Cascade, an online medical portal. Release

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

Gilead is working to move CAR-T med Yescarta into other types of NHL, and if data from an interim trial look-in are any indication, it's on its way.